Aeglea BioTherapeutics appoints Linda Neuman as chief medical officer

Nov. 15, 2022 4:32 PM ETAeglea BioTherapeutics, Inc. (AGLE)By: Dania Nadeem, SA News Editor
  • Aeglea BioTherapeutics (NASDAQ:AGLE) said on Tuesday it had appointed Linda Neuman as the chief medical officer.
  • Neuman's appointment is an internal promotion from her previous role as Aeglea's senior vice president of clinical development.
  • Before Aeglea, Neuman served as vice president, clinical development at Catalyst Biosciences where she led the clinical development of their late-stage development program for a novel hemophilia treatment.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.